Summary. Higher self-efficacy in chronic disease patients is associated with higher development of self-management skills and increased quality-of-life. Quantification and monitoring of self-efficacy is therefore of importance. Self-efficacy in haemophilia patients has received little attention due to lack of standardized scales. To validate the novel Haemophilia-specific Self-Efficacy Scale (HSES) in haemophilia patients on prophylactic home treatment, haemophilia patients aged 1-18 years on prophylactic treatment ≥1 year were included from three Dutch Haemophilia Treatment Centres. The HSES consists of 12 items, relating to perceptions of the ability to function on a day-to-day basis with regard to patient's disease. Retest was performed in a subsample. Validity was proven by the General Self-Efficacy Scale and by the health-related quality-of-life assessment tool Haemo-QoL. Data were analysed from 53 children (response 75%), with a mean age of 9.8 years (SD 4.0). Mean total scale score of HSES was 55.5 (SD 4.7; range 38-60), with a ceiling effect of 17%. The HSES showed adequate internal consistency (Cronbach's alpha 0.72) and good test-retest reliability (Intra-Class-Correlation coefficient 0.75; P < 0.01; n = 37). The convergent validity was adequate as haemophilia-specific selfefficacy correlated significantly with general selfefficacy (r = 0.38; P < 0.01). High HSES scores correlated significantly with quality-of-life as measured by the Haemo-QoL (r = À0.42; P ≤ 0.01). The novel HSES is a reliable and valid tool to assess self-efficacy in paediatric haemophilia patients on prophylactic home treatment. High self-efficacy correlated with higher quality-of-life, further underlining the importance to standardly assess, monitor and improve self-efficacy.
Introduction
In haemophilia, as in other chronic diseases, self-management skills of patients and caretakers are of relevance for treatment adherence, prognosis of disease and quality-of-life [1] . Prophylactic replacement therapy with clotting factor concentrate in the home setting requires a high ability of self-management as organization of care is complex (Lock J, Raat H, Duncan N, Shapiro A, Beijlevelt M, Peters M, Tamminga RYJ, Leebeek FWG, Moll HA, Cnossen MH, Submitted; [2] ). It includes insight on the necessity and dosing of clotting factor concentrate, taking prior prophylactic doses into account. Also practical and logistic capacities are of significance with regard to clotting factor concentrate infusion, stock and timely communication with the Haemophilia Treatment Centre (HTC).
Bandura developed the concept of 'self-efficacy'. This term describes the actual confidence an individual possesses with regard to specific actions necessary to achieve certain results [3] . It summarizes the integration of a motivated attitude towards a disease and its treatment, a capacity towards adequate judgment with regard to therapeutic interventions and demonstration of adherence to prescribed therapy [4] . Patients with low self-efficacy are less likely to persevere in a specific task when impediments arise, obliterating usual proceedings. Those with high self-efficacy will deploy all abilities to master obstacles. In clinical practice, selfefficacy is considered an antecedent for modification of behaviour [5, 6] . Furthermore, development of diseasespecific self-efficacy questionnaires is required to take disease-specific aspects into account not dealt with by the current validated general questionnaire.
In various chronic diseases high levels of self-efficacy are associated with higher quality-of-life and less clinical and psychological symptoms [5, [7] [8] [9] . In addition, Richardson et al. reported that patients with a wide range of chronic diseases value self-efficacy highly, and are willing to trade reductions in healthrelated quality-of-life for improvements in their selfefficacy [10] . In haemophilia, a number of studies have evaluated general self-efficacy and possible training modules, but few have looked at disease-specific self-efficacy.
Kang et al. proved that a self-help program for mothers of children with haemophilia significantly improved knowledge, self-efficacy and quality-of-life [11, 12] . Mulders et al. reported that an educational e-learning program in patients on prophylactic home treatment significantly improved general knowledge of treatment [13] . However, in this cohort, self-efficacy scores were relatively high at initiation and did not increase after intervention. Conflicting results were found by Barlow et al. and Buxbaum et al., as the first documented high levels of self-efficacy in haemophilia patients, indicating a well-developed confidence with regard to disease management, whereas the latter found lower self-efficacy scores in haemophilia patients than in healthy controls [14, 15] . All studies were performed using a general self-efficacy scale or a non-validated Haemophilia-specific Self-Efficacy Scale (HSES) as there was no validated HSES available. To adequately quantify and monitor self-efficacy and to identify subgroups at risk of higher morbidity and decreased quality-of-life, the HSES was recently developed and validated. This study aims to describe the psychometric properties of this novel instrument and the association between HSES and quality-of-life.
Patients and methods

Patients
Data for this cross-sectional, multicentre study were collected as part of a larger prospective study on the efficacy of home-treatment intervention by a trained haemophilia nurse (Netherlands Trial Register: 2543). Between June 2010 and December 2011, we enrolled children aged 1-18 years with haemophilia A or B on prophylaxis and home treatment for at least 1 year, from three HTC's in the Netherlands (Erasmus Medical Centre -Sophia Children's Hospital, Rotterdam; Academic Medical Centre -Emma Children's Hospital, Amsterdam; University Medical Centre Groningen). Patients and parents were required to speak and understand Dutch sufficiently. Patients with inhibitors against FVIII or FIX were excluded. One caregiver, primarily involved in the child's daily haemophilia treatment, and adolescents aged 10-18 years were asked to complete the questionnaire. To evaluate test-retest reliability of HSES, the questionnaire was sent two weeks after administration of the first questionnaire to consenting participants. Participants not returning the questionnaires within 2 weeks received reminders and were considered lost to follow-up after two unreturned messages. The Medical Ethical Committee granted permission to perform the study and written informed consent was obtained [MEC2010097].
Data collection
Socio-demographic data, including parental level of education, employment status and family structure were provided. For level of education the International Standard Classification of Education (ISCED) division into low, medium and high educational levels was applied [16] . Low is equivalent to ISCED 0-2, i.e. 'less than upper secondary level'; medium to ISCED 3-4, i.e. 'upper secondary level' and high to ISCED 5-6, meaning tertiary level, or minimally 2 years of education after upper secondary level. Haemophilia diagnosis, treatment and clotting factor consumption were extracted from medical files.
Self-efficacy
Haemophilia-specific Self-Efficacy Scale To specify disease-specific self-efficacy qualities, a novel scale was developed and validated, specifically for haemophilia patients. The HSES was composed by a team of haemophilia professionals and psychologists with items from the validated Sickle Cell Self-Efficacy Scale [7, 17] , from the Pain Self-Efficacy Questionnaire [18] and from the validated General Self-Efficacy Scale [19, 20] . The first two questionnaires were used as they specifically encompass disease aspects such as periodic immobilization and pain. The novel HSES consists of 12 items focusing on an individual's perceptions of haemophilia disease symptoms and the patient's abilities to cope with or reduce these symptoms. In our view, all aspects of treatment are incorporated: treatment efficacy, quality-of-life, infusion technique, state of mind in case of a bleed, pain modification, confidence, modification of prophylactic regimen, continuation of daily activities, other therapeutic interventions besides clotting factor treatment, belief in leading of a normal life, communication and attainment of personal goals. Items are scored ranging from 'I totally disagree' to 'I totally agree' (see figure) . On a fivepoint Likert-scale, the lowest score was given one point and the highest score five points. An unweighted sum score was calculated by adding the 12 item scores, with higher scores indicating greater self-efficacy (range: 12-60).
General Self-Efficacy Scale (GSES)
To assess the convergent validity of the HSES, we used the validated General Self-Efficacy Scale (GSES) [19, 20] . The GSES consists of 10 items on a four-point Likert-scale, ranging from 'I totally disagree' to 'I totally agree', with sum scores ranging from 10 to 40. Higher scores also indicate greater general self-efficacy. Although self-efficacy is considered to be task-specific, we assumed the concepts of general self-efficacy and haemophilia-specific self-efficacy to be related, which is supported by literature in other diseases, when assessing self-efficacy [21] .
Haemo-QoL
The disease-specific quality-of-life instrument HaemoQoL was used to assess the divergent construct validity. This is a self-report measure for children with haemophilia and their parents, consisting of 21-77 items which cover 9-11 domains depending on the age group of the patient. Higher scores indicate lower disease-specific quality-of-life [22] .
VERITAS-Pro
To quantify treatment adherence in children on prophylaxis, we used the Validated Haemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERI-TAS-Pro) (Lock J, Raat H, Duncan N, Shapiro A, Beijlevelt M, Peters M, Tamminga RYJ, Leebeek FWG, Moll HA, Cnossen MH, Submitted; [2] ). This instrument contains six subscales ('Time', 'Dose', 'Plan', 'Remember', 'Skip', 'Communicate'), each represented by four questions concerning a specific domain of haemophilia patient care. Cumulative score of all subscales ranges from 24 to 120 and cumulative scores per subscale range from 4 to 20. Lower scores reflect higher adherence.
Data analysis
Psychometric properties of HSES
The following psychometric properties of the HSES were evaluated as follows: feasibility, reliability and validity (convergent and divergent validity). Feasibility was expressed as response rate. Scale scores were described in terms of scale mean, SD, range, floor and ceiling effects and percentiles.
The total scale internal consistency reliability was assessed using Cronbach's alpha. Amidst varying standards in the literature, we considered 0.70 to be an acceptable alpha coefficient [23] .
The test-retest reliability was assessed by the IntraClass-Correlation Coefficients (ICC). The agreement between the perceived haemophilia-specific self-efficacy of parents and adolescents was also assessed by the ICC.
Validity was assessed by comparing HSES outcomes with the validated GSES and the Haemo-QoL. It was hypothesized that a low HSES outcome should correlate with low self-efficacy outcomes on the GSES and a low quality-of-life (i.e. higher score) by Haemo-QoL. As data were not normally distributed correlations in overall median sum scores were calculated and tested with Spearman's correlation coefficient. Low haemophiliaspecific self-efficacy was defined as the lowest quartile of HSES scores, while high haemophilia-specific selfefficacy was defined as the highest quartile of HSES scores as data were not distributed normally.
Subgroup analyses were assessed by comparing HSES outcomes with age, duration of prophylactic home treatment, number of siblings, level of education, marital status and family composition. We compared the patient group with the lowest quartile of HSES scores with the patient group with the highest quartile of HSES scores. Due to non-parametrical data, the continuous outcomes were assessed using the Mann-Whitney U-test and categorical data were analysed by Chi-square test or the Fisher's exact test in case of low patient counts per subgroup.
Data were analysed separately for parent-reported and adolescent-reported scales, except for the interrater agreement analysis which compared adolescentreported with parent-reported scales.
We considered P-values <0.05 as statistically significant; all tests were two-sided. All analyses were performed using SPSS 20.0 for Windows.
Results
Participants
A total of 71 patients of which 40 adolescents (10-18 years) were invited for study participation. Eighteen parents of children, including parents of 12 adolescents declined or did not fill out the questionnaire. Reasons for non-participation included time burden and logistical reasons. Fifty-three parents of both young children and adolescents (parent-reported questionnaires; response 75%) and 28 adolescents (adolescent-reported questionnaires; response 70%) were participated. Table 1 describes the baseline characteristics of all participants.
All 53 children were male with a mean age of 9.8 years (SD 4.0), 81% were diagnosed with haemophilia A, 89% had severe haemophilia. Of the 53 children, 28 were adolescents. The mean age of this subgroup was 13.6 (SD 2.5). Mean duration of prophylactic treatment was 7.1 years (SD 3.6), with a median time span between prophylaxis initiation and start of the home treatment of 0.5 years. Of the 53 parents, the majority was female (88%), 8% were educated at a low level, 20% were single parents and 30% had two children or more. Table 2 displays the total scale scores. Mean total scale scores were relatively high (55.5 for the parent-report and 55.7 for the adolescent-report) as were the median scores (57.0 for both the parent-and the adolescent-report). Floor effects were absent. Ceiling effects were observed in 17% of the parents and in 29% of the adolescents.
Psychometric properties of the HSES
The Cronbach's alpha of the total scale was a = 0.72 for the parent-report and a = 0.86 for the adolescent-report, indicating an adequate internal consistency ( Table 2) .
The test-retest reliability showed promising results, with a ICC of 0.75 (95%CI 0.56:0.86; P < 0.01; n = 37) for the parent-report and 0.67 (95%CI 0.29:0.87; P < 0.01; n = 17) for the adolescent-report. For the parent-report there was no significant difference between the test (mean 55.70; SD 4.16) and the retest (mean 55.88; SD 4.87; P = 0.34); also the adolescent-report showed identical results (test mean 55.88; SD 4.87; retest mean 55.18; SD 3.89; P = 0.37). The agreement between the perceived haemophilia-specific self-efficacy of parents and adolescents was however not significant (ICC À0.05; 95%CI À0.43:À0.35; P = 0.59).
Significant Spearman's correlations were observed with the General Self-Efficacy Scale (parent-report: r = 0.43; P < 0.05; adolescent-report: r = 0.81; P < 0.01). For the quality-of-life determined by the Haemo-QoL, the correlation of the total score was only significant for the parent-report of the HSES (r = À0.45; P < 0.01) and not significant for the adolescent-report HSES (r = 0.02; P = 0.92). Parents with a higher perceived self-efficacy (HSES) reported significantly less adherence with regard to subscales 'Plan', 'Remember' and 'Communication' on the VERITASPro scale when compared with parents with a lower perceived self-efficacy (respectively r = À0.28; r = À0.29; r = 0.37; P < 0.05). No other correlations were seen between the HSES (parent-report), the HSES (adolescent-report) and other VERITAS-Pro (sub)scales (Table 3) .
Parents with HSES scores in the lowest quartile reported significantly lower median scores on the: GSES (P < 0.01); the Haemo-QoL (sub)scales 'Total score' (P < 0.01), 'Feeling' (P = 0.02), 'View' (P = 0.01), 'Others' (P = 0.03), and 'Sport' (P < 0.01); and on the VERITAS-Pro subscales 'Remember' (P = 0.05), 'Skip' (P < 0.01) and 'Communicate' (P = 0.01), compared to parents with HSES scores in the highest quartile (Table 4) . Adolescents with HSES scores in the lowest quartile reported significantly lower median scores on the: GSES (P < 0.01); the Haemo-QoL subscales 'Others' (P = 0.04) and 'Treatment' (P = 0.02), compared to adolescents with HSES scores in the highest quartile (Table 4) . Perceived disease-specific self-efficacy was not associated with age, duration of prophylactic treatment, level of education, number of siblings, marital status or with family composition. Neither in parents nor in adolescents (data not shown).
Discussion
The novel HSES is a feasible and reliable instrument to evaluate self-efficacy in Dutch paediatric patients with haemophilia on prophylactic home treatment. As timely communication and intervention is obligatory to modify prognosis in a disease with periodic episodes of pain and immobilization, we believe regular evaluation of self-efficacy is essential. In our study, HSES showed satisfactory psychometric properties and was able to discriminate between high and low self-efficacy. High HSES scores correlated significantly with quality-of-life measured by the Haemo-QoL. Further evaluation in other populations with regard to age and cultural background is necessary to broaden application possibilities of this valuable tool. Differentiation of subgroups within the haemophilia patient population with regard to self-efficacy is of paramount importance to identify potential high-risk patients with an increased risk of morbidity and decreased quality-of-life [24, 25] . Subsequently, patients may undergo interventions aiming to increase self-efficacy, ultimately leading to cost-reduction of treatment in this era of rising health care costs.
Strengths of the HSES are diverse. Firstly, the 12 items chosen cover all aspects of haemophilia care in which self-efficacy plays a role and follow the definition of self-efficacy as described by Bandura in 1977 [3] . Secondly, general self-efficacy and disease-specific self-efficacy correlated significantly as did a higher self-efficacy with a higher quality-of-life as evaluated by HaemoQoL, a validated and widely used tool to analyse quality-of-life in children and adolescents with haemophilia. Furthermore, a high response rate was reached among the study population, leading to reliability of conclusions. Fourthly, as the HSES is an easily applied tool, it will allow monitoring of interventions aimed to improve haemophilia-specific self-efficacy. Finally, HSES is another example of a combination of qualitative research and quantitative survey techniques, such as seen in the development of the VERITAS-Pro by Duncan et al. [2] . In our opinion, this approach leads to richer, more valid and more reliable findings, with clear clinical implications, than when adopting qualitative or quantitative methods alone [26] .
The limitations of our study are discussed. Firstly, some may deliberate the capturing of self-efficacy by a limited number of questions with fixed answering categories. However, we have chosen to make HSES a feasible tool in daily clinical practice: quick, reliable and valid. Secondly, the lack of patient report in constructing of the questionnaire is an omission as solely expert opinion of haematologists, haemophilia nurses and clinical psychologists was employed. Therefore, patient interpretation of questions may differ. Thirdly, due to practical reasons we were forced to exclude patients with language difficulties due to the questionnaire-based nature of the study. We are thoroughly aware, that specifically this group is characterized by low self-efficacy and decreased adherence to medical treatment [27] . Just as patients with inhibiting antibodies against FVIII/FIX, may also be characterized by low self-efficacy. We excluded this group, due to the fact that their intensive treatment has such a severe impact on daily life that it is not comparable to standard prophylactic treatment. Exclusion of these groups may have biased results towards underreporting of low self-efficacy. However, despite exclusion of these groups, HSES still differentiates between high and low self-efficacy [28] , proving the sensitivity of the tool and its applicability in daily clinical practice. Fourthly, we administered a parent-report asking how parents perceive their own self-efficacy, but unfortunately omitted how they perceive the self-efficacy of their children, which would have been a valuable addition. Furthermore, statistical analysis of subgroups was of course limited by small sample size. We therefore recommend future studies to assess reliability and validity in other subgroups of patients, and in other settings and to utilize other qualitative research methods such as cognitive debriefing. Haemophilia-specific Self-Efficacy Scale properties were satisfactory. A floor effect was absent as is frequently the case in positively skewed assessments of reported self-efficacy [21, 29, 30] . Skewing was observed towards the most positive category ('ceiling effect') as often reported in other surveys on self-efficacy in chronic diseases [21, 29, 30] . This limitation effects the discrimination between participants with a high self-efficacy and restricts participants with a high self-efficacy to acquire better scores in a followup assessments. The ceiling effect can be explained by several factors such as the extensive education of patients and parents with regard to disease. In addition, current treatment focuses intensively on selfmanagement skills, patients and parents have been dealing with the disease for a longer period of time, and multiple family members may be affected, leading to more disease experience.
The HSES scale questionnaire's internal consistency was good. Cronbach's alpha coefficients in similar questionnaires were comparable [7, 17, 31] . The testretest reliability was adequate both in parents and adolescents. The agreement between the perceived haemophilia-specific self-efficacy of parents and adolescents showed no correlation, as is often seen when comparing parent-reported and adolescent-reported outcomes on self-efficacy and quality-of-life questionnaires [32, 33] . This is most likely explained by the differences in treatment experience between parents and adolescents as well as diverging management responsibilities between parents and adolescents.
The convergent and divergent validity analyses of HSES showed promising test results, which is of paramount importance to discriminate between optimal and less optimal self-efficacy and to promote its future use. Both parents and adolescents clearly expressed similar opinions on their HSES report and their general self-efficacy report. In addition, parents also showed similar opinions on their disease-specific selfefficacy as expressed by the HSES and quality-of-life measurements by Haemo-QoL. However, the latter was only observed in some subscales of the HaemoQoL in adolescents. Most probably, outcome is influenced by growing and not yet complete responsibility of adolescents for their disease, which directly correlates with self-efficacy outcome and not with quality-of-life outcome. Adequate transition towards disease responsibility is of course expected of the adult haemophilia patient. This development could be measured and monitored by HSES, making it an important tool in the challenging transitional period [7, 34, 35] .
In line with our hypothesis, we found that adherence to administered clotting factor concentrate doses in relationship to prior prophylactic doses (subscales 'Remember' and 'Skip') was higher in parents with a higher perceived haemophilia-specific self-efficacy. In contrast, we found evidence that adherence to communication with the HTC determined by the VERI-TAS-Pro was significantly lower in parents with a high perceived disease-specific self-efficacy than in parents with a low perceived self-efficacy. Our hypothesis is that the latter may be the consequence of the welldeveloped self-management strategies of these parents, decreasing communication moments. Further research is necessary to objectify patient outcome in these patients.
Conclusion
The HSES shows satisfactory psychometric properties to describe the self-efficacy in paediatric haemophilia patients on prophylactic home treatment. HSES parent-report correlated with quality-of-life measures, further underlining the importance to standardly assess, monitor and improve self-efficacy. Validation in other cohorts is impending to augment the value of HSES.
